SNOA - Sonoma Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Sonoma Pharmaceuticals, Inc.

1129 North McDowell Boulevard
Petaluma, CA 94954
United States
707-283-0550
http://www.sonomapharma.com

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees62

Key Executives

NameTitlePayExercisedYear Born
Mr. Bruce ThorntonExec. VP of International Operations & Sales310.51kN/A1964
Dr. Robert NortheyExec. VP of R&D251.83kN/A1957
Ms. Amy M. TromblyInterim Chief Exec. OfficerN/AN/A1968
Mr. R. Grant EdwardsChief Financial OfficerN/AN/A1978
Ms. Victoria CovelAssistant ControllerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions, as well as Loyon for the management of scaling and itch. It also provides Mondoxyne, a doxycycline-based prescription oral tetracycline antibiotic used as a treatment for acne vulgaris; Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; and Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

Corporate Governance

Sonoma Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.